A Study of Obinutuzumab as Maintenance Therapy for People With Primary Central Nervous System Lymphoma

Full Title

Purpose

Researchers are assessing obinutuzumab in people with primary central nervous system lymphoma (PCNSL) whose cancer responded to initial treatment. They want to see if obinutuzumab increases the time without the disease returning or getting worse. This type of treatment is called maintenance therapy.

The people in this study have PCNSL that makes the CD20 protein. Obinutuzumab works by binding to the CD20 protein on B cells (a type of white blood cell). By targeting and blocking these proteins, obinutuzumab may help slow or stop the growth of cancer cells.

If you join this study, you will be randomly assigned to one of these groups:

• Obinutuzumab given intravenously (by vein).
• Observation (no obinutuzumab, but you are watched closely to see if the PCNSL comes back).

Who Can Join

To join this study, there are a few conditions. You must:

• Have achieved a partial or complete response to initial PCNSL therapy.
• Have finished initial treatment within 75 days of starting the study.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information about this study or to see if you can join, please call Dr. Christian Grommes’ office at 212-610-0344.